Treatment of essential thrombocythemia with anagrelide.
作者信息
Chintagumpala M M, Kennedy L L, Steuber C P
机构信息
Department of Pediatrics, Texas Children's Cancer Center, Houston 77030, USA.
出版信息
J Pediatr. 1995 Sep;127(3):495-8. doi: 10.1016/s0022-3476(95)70090-0.
PMID:7658287
Abstract
Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by persistent elevation in platelet count. It is a rare disorder in children, and children who have symptoms require treatment. We report the successful use of anagrelide, with few toxic effects, in the treatment of three children with ET.
摘要
Zotero 插件